| Literature DB >> 27509379 |
Adlette Inati1, Anthony G Mansour, Toni Sabbouh, Ghid Amhez, Ahmad Hachem, Hussein A Abbas.
Abstract
Hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation represent the 3 disease-modifying therapies in children with sickle cell disease (SCD). Blood transfusions play an increasingly important role in both prevention and management of SCD complications in this age group. This review will focus on the indications of blood transfusion in children with SCD and modalities of its administration. It will also highlight the complications of this life-saving therapy and ways of optimizing transfusion to minimize its associated risks.Entities:
Mesh:
Substances:
Year: 2017 PMID: 27509379 DOI: 10.1097/MPH.0000000000000645
Source DB: PubMed Journal: J Pediatr Hematol Oncol ISSN: 1077-4114 Impact factor: 1.289